611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Basic InformationLatest News
Too Little Vitamin D Could Raise Colon Cancer Risk in Black WomenTargeted High-Dose Radiation Helps Fight Advanced Lung CancerCancer Costs U.S. Patients $21 Billion a YearWhy Are Cases of Pancreatic Cancer Rising in Young Women?Quit Smoking Before 45 & Wipe Out 87% of Lung Cancer RiskJust 5 Hours of Moderate Exercise a Week Cuts Your Cancer RiskWhen Cancer Strikes, Who's at Higher Risk for Suicide?Powell's COVID Death Despite Vaccination Shows Danger to Those With Weakened Immune SystemsTreating Depression Could Lengthen Lung Cancer Patients' LivesResearchers Find Better Way to Fight Breast Cancer That Has Spread to BrainCancer Care Costs U.S. $156 Billion Per Year; Drugs a Major FactorNearly Half of U.S. Breast Cancer Patients Use Pot or CBD; Many Don't Tell DoctorsAnti-Nausea Drug May Boost Survival for Some Cancer PatientsYour Free Cancer Screen Shows Trouble: What If You Can't Afford the Follow-Up?Access to Top Drugs Makes the Difference for Black Lung Cancer PatientsWhy Skin Cancer Checks Are Even More Important for Hispanic People1 in 7 Cancer Patients Worldwide Missed a Surgery Due to PandemicAI Helps Rule Out Cancer in Women With Dense BreastsExisting Drugs Could Treat Lung Cancer in NonsmokersColon Cancer Diagnoses Fell 40% in Pandemic, and That's Not Good NewsRacial Disparities Persist With Childhood CancersNew Tests for Colon, Prostate Cancer Show PromiseTough Choices: Chemo That Can Save Kids With Cancer Can Also Damage HearingCan a Computer Program Help Docs Spot Breast Cancer?Trials Show COVID Vaccines Well Worth It for Cancer PatientsCancer in Hispanics: Good News and BadRadiation Therapy for Breast Cancer May Have Long-Term Risk for the HeartCommon Form of Liver Cancer on the Rise in Rural AmericaNew Drug Combo Boosts Survival Against Aggressive Form of Breast CancerPeople With MS Have Worse Survival If Colon Cancer StrikesHaving Even a Cousin or Grandparent With Colon Cancer Raises Your Risk: StudyBlood Cancer Patients Could Benefit From COVID Booster Shot: StudyYour State's Laws Might Save Your Life If Breast Cancer Strikes9/11 First Responders Face Higher Cancer Risk 20 Years LaterChild Cancers Are Rare, But Here Are Signs to Look ForIn Cancer Patients, COVID Vaccine Immunity at 6 Months Is Similar to General PopulationWhich Cancer Patients Need a COVID Booster Shot Most?AI May Not Be Ready to Accurately Read MammogramsToo Many Antibiotics Might Raise Colon Cancer RiskPandemic Brought Big Drop in Breast Cancer Screening in Older, Low-Income WomenFewer American Adults Are Getting Malignant Brain TumorsDon't Forget to Apply Sunscreen Before & After Water FunExercise Could Help Fight 'Chemo Brain' in Breast Cancer PatientsSpotting the Signs of Deadly Melanoma Skin CancersVitamin D Might Help Prevent Early-Onset Colon CancerFar Too Few People of Color in U.S. Pancreatic Cancer TrialsDeath of Spouse Could Raise Men's Odds for Prostate CancerCancer Patients Avoiding Pot, Even as Rules on Use RelaxOne Key Question Can Help Spot Skin CancerImmune-Based Therapy May Help Some Battling Advanced Colon Cancers
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

New Drug Combo Boosts Survival Against Aggressive Form of Breast Cancer

HealthDay News
by By Denise Mann HealthDay Reporter
Updated: Sep 20th 2021

new article illustration

MONDAY, Sept. 20, 2021 (HealthDay News) -- New research offers good news for women with an aggressive HER2-positive breast cancer.

A targeted therapy, trastuzumab deruxtecan (T-DXd), sold as Enhertu, triples the length of time that the cancer remains in check when compared with the current gold standard, trastuzumab emtansine (T-DM1).

"It really truly blew T-DM1 out of water in terms of progression-free survival," said study co-author Dr. Sara Hurvitz, director of breast cancer clinical research at UCLA's Jonsson Comprehensive Cancer Center.

Up to 20% of breast cancers are HER2-positive, meaning there's too much of a protein called human epidermal growth factor receptor 2 on the cell's surface, causing the cancer to act more aggressively, explained Hurvitz.

Currently, the first-line therapy for women with this type of breast cancer is HER2 antibody therapy with pertuzumab/trastuzumab plus chemotherapy. If the cancer progresses, the standard care is to switch to T-DM1 (sold as Kadcyla), which comprises trastuzumab and chemotherapy.

But the new study may change this paradigm, Hurvitz said.

Given intravenously, T-DXd attaches to the HER2 protein, blocking its growth, and delivers high concentrations of chemotherapy directly to cancer cells that overexpress HER2.

The new study was funded by T-DXd manufacturers Daiichi Sankyo Inc. and AstraZeneca.

In the study of 524 women with HER2-positive breast cancer, those who received T-DXd had a 72% improvement in their progression-free survival compared to their counterparts who were treated with T-DM1.

At one year, 76% of women taking T-DXd didn't show any signs of disease progression. By contrast, only 34% of women taking T-DM1 did not see disease progression at one year.

"This drug really lengthens progression-free survival time or time before a patient needs to switch therapies because the one that they are on has stopped working and their disease gets worse," Hurvitz said. "This is very good news for patients."

In addition, tumors shrank in close to 80% of women taking T-DXd, compared to only 34% treated with T-DM1. Fully 16% of T-DXd-treated women showed no evidence of disease at one year, the study showed. The new drug seemed to work especially well in women whose breast cancer had spread to their brain, Hurvitz said.

The findings were presented this weekend at the annual meeting of the European Society for Medical Oncology. Research presented at meetings is typically considered preliminary until published in a peer-reviewed journal.

One of the main safety concerns with this drug is the risk of interstitial lung disease, a group of lung conditions that causes scarring of lung tissues, Hurvitz said. The risk was low in the new study, and the women who did develop interstitial lung disease tended to have mild cases, she said.

Outside experts are equally enthusiastic about the study findings and what they may mean for women with advanced HER2-positive breast cancer.

"T-DXd represents a new standard of care, used in place of TDM-1, in advanced HER2-overexpressing breast cancers," said Dr. Charles Shapiro. He is a professor of medicine, hematology and medical oncology at Icahn School of Medicine at Mount Sinai and a medical breast oncologist at Mount Sinai Tisch Cancer Center in New York City. "The world is brighter for women with HER2 overexpressing breast cancers."

"This study may lead to a change in the standard of care for patients with metastatic HER2-positive breast cancer," said Dr. Jesus Anampa Mesias, a medical oncologist at Montefiore Einstein Cancer Center in New York City. "The results of this study are impressive and unprecedented [and] will definitely change how I care for women with metastatic HER2-positive breast cancer."

More information

Learn more about HER2-positive breast cancer at the American Cancer Society.

SOURCES: Sara Hurvitz, MD, director, Breast Cancer Clinical Research Program, Jonsson Comprehensive Cancer Center, UCLA; Charles Shapiro, MD, professor, medicine, hematology, and medical oncology, Icahn School of Medicine, Mount Sinai, and medical breast oncologist, Mount Sinai Tisch Cancer Center, New York City; Jesus Anampa Mesias, MD, medical oncologist, Montefiore Einstein Cancer Center, New York City; European Society for Medical Oncology Congress, Sept. 16-21, 2021